Happy Farm Botanicals – FDA Warning Letter, Apr 2, 2026

Happy Farm Botanicals, Inc. received a formal warning letter from the FDA following an inspection of its Hyattsville, Maryland facility conducted from March 30 to April 2, 2026. The inspection revealed significant failures to comply with Current Good Manufacturing Practice (CGMP) regulations under the Federal Food, Drug, and Cosmetic Act, rendering the firm’s over-the-counter drug products adulterated. Key violations included a failure to perform adequate identity testing on raw materials, relying instead on unverified supplier certificates and sensory observations. Additionally, the firm lacked a robust stability testing program to support labeled expiration dates and failed to investigate products that did not meet quality specifications. The Quality Control Unit was found to be deficient in its oversight, failing to validate manufacturing processes and equipment cleaning procedures. The FDA noted that many of these issues were repeat observations from a 2024 inspection, indicating a systemic lack of management control. Although the company has ceased drug production at this facility, the FDA requires several actions before operations can resume. These include a comprehensive independent review of the material and supplier system, a full remediation of the stability program, and a complete assessment of quality unit authority. If the firm intends to restart manufacturing, it must hire a qualified consultant to conduct a six-system audit and provide a risk assessment for products currently in distribution. Failure to address these deficiencies may result in legal action, including product seizures or injunctions.